1,102 results

#105540-AAV8

Ready-to-use AAV8 particles produced from pENN.AAV.hSyn.HI.eGFP-Cre.WPRE.SV40 (#105540). In addition to the viral particles, you will also receive purified pENN.AAV.hSyn.HI.eGFP-Cre.WPRE.SV40 plasmid DNA. Expression of EGFP-Cre from hSyn promoter. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

March 12, 2021

Academic Institutions and Nonprofits only

#75470-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-FLEXFRT-ChR2(H134R)-mCherry (#75470). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEXFRT-ChR2(H134R)-mCherry plasmid DNA. CAG-driven, Flp recombinase-dependent expression of channelrhodopsin H134R mutant fused to mCherry. These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Elife. 2016 May 20;5. pii: e15312. doi:

March 2, 2020

Academic Institutions and Nonprofits only

#20297-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 15, 2018

Academic Institutions and Nonprofits only

#27056-AAV2

Ready-to-use AAV2 particles produced from pAAV-Ef1a-DIO EYFP (#27056). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO EYFP plasmid DNA. EF1a-driven, cre-dependent EYFP expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 15, 2018

Academic Institutions and Nonprofits only

#121675-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-fDIO-Cre (#121675). In addition to the viral particles, you will also receive purified pAAV-EF1a-fDIO-Cre plasmid DNA. EF1a-driven, Flp recombinase dependent expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Esteban Engel, Alexander Nectow

Schneeberger et al Cell. 2019 Jun 24. pii: S0092-8674(19)30

Sept. 27, 2023

Academic Institutions and Nonprofits only

#50476-AAV9

Ready-to-use AAV9 particles produced from pAAV-CaMKIIa-hM3D(Gq)-mCherry (#50476). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hM3D(Gq)-mCherry plasmid DNA. CaMKIIa-driven hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 26, 2021

Academic Institutions and Nonprofits only

#50475-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-hM4D(Gi)-mCherry (#50475). In addition to the viral particles, you will also receive purified pAAV-hSyn-hM4D(Gi)-mCherry plasmid DNA. CNO-induced neuronal silencing. Synapsin-driven with mCherry reporter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Aug. 23, 2017

Academic Institutions and Nonprofits only

#160857-AAV8

Ready-to-use AAV8 particles produced from pAAV-FLEx-ER-TurboID (#160857). In addition to the viral particles, you will also receive purified pAAV-FLEx-ER-TurboID plasmid DNA. CMV-driven, Cre-dependent expression of ER-localized TurboID (with HA and V5 tag). These AAV preparations are suitable purity for injection into animals.

Jonathan Long

Wei et al Nat Chem Biol. 2021 Mar;17(3):326-334. d

Aug. 6, 2025

Academic Institutions and Nonprofits only

#140554-AAV9

Ready-to-use AAV9 particles produced from pAAV-hsyn-GRAB_DA2h (#140554). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_DA2h plasmid DNA. Synapsin-driven expression of high-affinity GRAB_DA2h dopamine sensor in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Nat Methods. 2020 Nov;17(11):1156-1166.

Aug. 9, 2021

Academic Institutions and Nonprofits only

#191737-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP12610 - pAAV-AiE0780m-minBG-SYFP2-WPRE3-BGHpA (Alias: CN2610) (#191737). In addition to the viral particles, you will also receive purified AiP12610 - pAAV-AiE0780m-minBG-SYFP2-WPRE3-BGHpA (Alias: CN2610) plasmid DNA. minBG-driven expression of SYFP2 in striatal direct pathway medium spiny neurons (D1-MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 13, 2024

Academic Institutions and Nonprofits only

#100836-AAV9

Ready-to-use AAV9 particles produced from pAAV.CAG.GCaMP6f.WPRE.SV40 (#100836). In addition to the viral particles, you will also receive purified pAAV.CAG.GCaMP6f.WPRE.SV40 plasmid DNA. CAG-driven GCaMP6f calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

March 19, 2018

Academic Institutions and Nonprofits only

#117382-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Oct. 18, 2021

Academic Institutions and Nonprofits only

#171027-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-fDIO-ChrimsonR-tdTomato (#171027). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-ChrimsonR-tdTomato plasmid DNA. Flp-dependent, Ef1a-driven expression of ChrimsonR-tdTomato fusion for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Patricia Jensen

Sciolino et al Sci Adv. 2022 Aug 19;8(33):eabn9134. doi

June 26, 2024

Academic Institutions and Nonprofits only

#172907-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-FLEX-Volton2-ST-WPRE (#172907). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-Volton2-ST-WPRE plasmid DNA. Cre-dependent, Syn-driven expression of the voltage sensor Voltron2-ST containing a soma localization targeting sequence. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Abdelfattah et al Neuron. 2023 Mar 28:S0896-6273(23)00205-

July 21, 2023

Academic Institutions and Nonprofits only

#26975-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CaMKIIa-hChR2(H134R)-mCherry (#26975). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-mCherry plasmid DNA. CamKIIa-driven, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Dec. 2, 2019

Academic Institutions and Nonprofits only

#20298-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Sept. 8, 2020

Academic Institutions and Nonprofits only

#137125-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-sRGECO (#137125). In addition to the viral particles, you will also receive purified pAAV-Ef1a-sRGECO plasmid DNA. EF1a-driven expression of cytosolic sRGECO calcium sensor. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 6, 2021

Academic Institutions and Nonprofits only

#55641-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Feb. 25, 2021

Academic Institutions and Nonprofits only

#123308-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-GRAB_NE1m (#123308). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_NE1m plasmid DNA. Synapsin-driven expression of GRAB-NE1m norepinephrine sensor in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Feng et al Neuron. 2019 May 22;102(4):745-761.e8. d

Nov. 19, 2019

Academic Institutions and Nonprofits only

#187179-AAV9

Ready-to-use AAV9 particles produced from pAAV_hSyn1_nLightG (#187179). In addition to the viral particles, you will also receive purified pAAV_hSyn1_nLightG plasmid DNA. Synapsin-driven expression of norepinephrine sensor nLightG. These AAV preparations are suitable purity for injection into animals.

Tommaso Patriarchi

Kagiampaki et al Nat Methods. 2023 Sep;20(9):1426-1436. d

June 21, 2024

Academic Institutions and Nonprofits only